Trials / Completed
CompletedNCT01802866
Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride
A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) With Placebo for the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 508 (actual)
- Sponsor
- Kubota Vision Inc. · Industry
- Sex
- All
- Age
- 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if emixustat hydrochloride (ACU-4429) reduces the rate of progression of geographic atrophy compared to placebo in subjects with dry age-related macular degeneration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACU-4429 | Take orally once daily for 24 months |
| DRUG | Placebo | Take orally once daily for 24 months |
Timeline
- Start date
- 2013-02-01
- Primary completion
- 2016-04-01
- Completion
- 2016-05-01
- First posted
- 2013-03-04
- Last updated
- 2017-07-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01802866. Inclusion in this directory is not an endorsement.